Citations

Clear

1792 citation(s) found for "Stephanie".

Whole‐body senescent cell clearance alleviates age‐related brain inflammation and cognitive impairment in mice
Ogrodnik, Mikołaj , Evans, Shane A., Fielder, Edward , Victorelli, Stella , Krüger, Patrick, Salmonowicz, Hanna , Weigand, Bettina M., Patel, Ayush , Pirtskhalava, Tamar , Inman, Christine, Johnson, Kurt O. , Dickinson, Stephanie , Rocha, Azucena, Schafer, Marissa , Zhu, Yi , Passos, João F. , Kirkland, James L. , Jurk, Diana , Patel, Ayush D, Inman, Christine L, Schafer, Marissa J, Jurk, Diana , Passos, João F , Schafer, Marissa J , Zhu, Yi , Allison, David B. , Zglinicki, Thomas von , LeBrasseur, Nathan K. , Tchkonia, Tamar , Neretti, Nicola

Mayo Clinic

Aging Cell | January 20, 2021 | Volume: 20 | Issue: 2 | Pages: No page available

10.1111/acel.13296 | PMID 33470505 Get It

Abstract Cellular senescence is characterized by an irreversible cell cycle arrest and a pro‐inflammatory senescence‐associated secretory phenotype (SASP), which is a major contributor to aging and age‐related diseases. Clearance of senescent cells has been shown to improve brain function in mouse models of neurodegenerative diseases. However, it is still unknown whether senescent cell clearance alleviates cognitive dysfunction during the aging process. To investigate this, we first conducted single‐nuclei and single‐cell RNA‐seq in the hippocampus from young and aged mice. We observed an age‐dependent increase in p16 Ink4a senescent cells, which was more pronounced in microglia and oligodendrocyte progenitor cells and characterized by a SASP. We then aged INK ‐ ATTAC mice, in which p16 Ink4a ‐positive senescent cells can be genetically eliminated upon treatment with the drug AP20187 and treated them either with AP20187 or with the senolytic cocktail Dasatinib and Quercetin. We observed that both strategies resulted in a decrease in p16 Ink4a exclusively in the microglial population, resulting in reduced microglial activation and reduced expression of SASP factors. Importantly, both approaches significantly improved cognitive function in aged mice. Our data provide proof‐of‐concept for senolytic interventions' being a potential therapeutic avenue for alleviating age‐associated cognitive impairment.
Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis
Dempsey, Timothy , Payne, Stephanie , Sangaralingham, Lindsey R. , Shah, Nilay D. , Dempsey, Timothy M , Yao, Xiaoxi , Limper, Andrew H.

Mayo Clinic

Annals of the American Thoracic Society | January 19, 2021 | Volume: 18 | Issue: 7 | Pages: 1121-1128

10.1513/annalsats.202007-901oc | PMID 33465323 Get It

Abstract Rationale In October 2014, the antifibrotic medications pirfenidone and nintedanib became the first medications approved by the U.S. Food and Drug Administration for use in patients with idiopathic pulmonary fibrosis (IPF). Since approval, there has been no nonregistry analysis of the real-world adoption of these medications in everyday clinical practice. Objectives To evaluate the adoption, persistence, and out-of-pocket (OOP) costs of pirfenidone and nintedanib since their approval in the United States in 2014. Methods A retrospective cohort analysis was performed by identifying privately insured and Medicare Advantage beneficiaries with IPF. We then split the patients into three cohorts: those who were untreated and those who filled a prescription for either pirfenidone or nintedanib between October 1, 2014, and July 31, 2019. The primary outcome was adoption of the medications. Secondary outcomes included medication persistence and prescription drug costs. Results A total of 10,996 patients with IPF were identified in the data set. A minority of patients (26.4%) with IPF identified in the cohort had started either medication since approval in 2014, with the adoption of both medications being comparable at around 13.2%. Those receiving the medications were younger (72 vs. 73.9 yr; P < 0.0001) and healthier (3.9 vs. 4.9 comorbidities; P < 0.0001) than those not receiving treatment. Men were significantly more likely to receive treatment than woman (30.0% vs. 21.9%; P < 0.0001). Among treated patients, 42.8% discontinued the medications during the study period. Patients’ OOP expenses per month were high for both drugs (mean, $397.51 for nintedanib; mean, $394.49 for pirfenidone). Conclusions The adoption of both the antifibrotic medications in the United States in everyday practice has been low since approval and may be associated with the high OOP cost.
Observation Versus Intervention for Low-Grade Intracranial Dural Arteriovenous Fistulas
Buell, Thomas J. , Ding, Dale , Guniganti, Ridhima , Kansagra, Akash P. , Brinjikji, Waleed , Kim, Louis J. , Levitt, Michael R. , Abecassis, Isaac Josh, Bulters, Diederik , Durnford, Andrew , Fox, W. Christopher , Polifka, Adam , Gross, Bradley A. , Hayakawa, M. , Derdeyn, Colin P. , Amin‐Hanjani, Sepideh , Alaraj, Ali , Kwasnicki, Amanda , Dijk, J. Marc C. van , Potgieser, Adriaan R. E., Starke, Robert M., Satomi, Junichiro, Tada, Yoshiteru , Abla, Adib A. , Lai, Rosalind, Zipfel, Gregory J. , Sheehan, Jason P. , Piccirillo, Jay F. , Vine, Roanna , Cloft, Harry J. , Kallmes, David F. , Pollock, Bruce E. , Link, Michael J., Rao, Mohana Patibandla, Paisan, Gabriella, Meyer, R. Michael, Kelly, Cory , Duffill, Jonathan, Ditchfield, Adam, Millar, John S. , Macdonald, Jason, Laurent, Dimitri , Lockerman, Ashley, Lunsford, L. Dade , Jankowitz, Brian T. , Guerrero, Waldo R. , McGruder, Allen, Charbel, Fady T. , Aletich, Victor , Rose‐Finnell, Linda, Peterson, Eric C. , Yavagal, Dileep R. , Samir, Sur, Kanematsu, Yasuhisa , Kinouchi, T. , Korai, Masaaki , Yamaguchi, Izumi , Yamamoto, Yuki , Winkler, Ethan A. , Lawton, Michael T. , Rutkowski, Martin J. , Sultan, M. Ali Aziz, Patel, Nirav J. , Frerichs, Kai U., Ding, Dale , Amin-Hanjani, Sepideh , Alaraj, Ali , Du, Rose , Levitt, Michael R , Fox, W Christopher , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Derdeyn, Colin P , Chen, Ching‐Jen , Lanzino, Giuseppe , Kim, Louis J. , Gross, Bradley , Samaniego, Edgar A , Chen, Stephanie , Phelps, Ryan , Raman, Hari S. , Lipsey, Kim L. , Giordan, Enrico , Link, Michael J. , Hoh, Brian L. , Smith, Jessica , Ortega-Gutierrez, Santiago , Hasan, David , Roa, Jorge A. , Rossen, James D. , Yamamoto, Nobuaki

Mayo Clinic

Neurosurgery | January 14, 2021 | Volume: 88 | Issue: 6 | Pages: 1111-1120

10.1093/neuros/nyab024 | PMID 33582776 Get It

Abstract BACKGROUND Low-grade intracranial dural arteriovenous fistulas (dAVF) have a benign natural history in the majority of cases. The benefit from treatment of these lesions is controversial. OBJECTIVE To compare the outcomes of observation versus intervention for low-grade dAVFs. METHODS We retrospectively reviewed dAVF patients from institutions participating in the CONsortium for Dural arteriovenous fistula Outcomes Research (CONDOR). Patients with low-grade (Borden type I) dAVFs were included and categorized into intervention or observation cohorts. The intervention and observation cohorts were matched in a 1:1 ratio using propensity scores. Primary outcome was modified Rankin Scale (mRS) at final follow-up. Secondary outcomes were excellent (mRS 0-1) and good (mRS 0-2) outcomes, symptomatic improvement, mortality, and obliteration at final follow-up. RESULTS The intervention and observation cohorts comprised 230 and 125 patients, respectively. We found no differences in primary or secondary outcomes between the 2 unmatched cohorts at last follow-up (mean duration 36 mo), except obliteration rate was higher in the intervention cohort (78.5% vs 24.1%, P < .001). The matched intervention and observation cohorts each comprised 78 patients. We also found no differences in primary or secondary outcomes between the matched cohorts except obliteration was also more likely in the matched intervention cohort ( P < .001). Procedural complication rates in the unmatched and matched intervention cohorts were 15.4% and 19.2%, respectively. CONCLUSION Intervention for low-grade intracranial dAVFs achieves superior obliteration rates compared to conservative management, but it fails to improve neurological or functional outcomes. Our findings do not support the routine treatment of low-grade dAVFs.
Premature ovarian insufficiency: a toolkit for the primary care physician
Lambrinoudaki, Ιrene , Lumsden, Mary Ann , Makrakis, Evangelos , Panay, Nick , Lambrinoudaki, Irene , Paschou, Stavroula Α. , Faubion, Stephanie S. , Kalantaridou, Sophia

Mayo Clinic

Climacteric | January 14, 2021 | Volume: 24 | Issue: 5 | Pages: 425-437

10.1080/13697137.2020.1859246 | PMID 33434082 Get It

Connecting Generations of Scientists in the Council on Hypertension Through Harriet Dustan
Baylis, Chris, Brown, Nancy J. , Cassis, Lisa A. , Denton, Kate M. , Joe, Bina , Lerman, Lilach O. , Oparil, Suzanne , Reckelhoff, Jane F. , Sandberg, Kathryn , Brown, Nancy J , Watts, Stephanie W. , Alexander, Barbara T. , Touyz, Rhian M. , Denton, Kate M

Mayo Clinic

Hypertension | January 4, 2021 | Volume: 77 | Issue: 2 | Pages: 296-307

10.1161/hypertensionaha.120.16623 | PMID 33390045 Get It

483: A Systematic Review Evaluating Mortality in Patients With Cancer Admitted to the Intensive Care Unit
Nazer, Lama , Sirimaturos, Michael , Al‐Qadheeb, Nada S. , Milano, Victoria, Habash, Khader , Nates, Joseph, Brown, Anne Rain , Cuenca, John A. , May, Heather P. , Taylor, Amy Grace Stephanie , Nates, Joseph L.

Mayo Clinic

Critical Care Medicine | December 18, 2020 | Volume: 49 | Issue: 1 | Pages: 232-232

10.1097/01.ccm.0000727820.04292.45 Get It

TIMELINE OF GAINS IN QUADRICEPS STRENGTH SYMMETRY AND PATIENT-REPORTED FUNCTION EARLY AFTER ACL RECONSTRUCTION
Pottkotter, Kristy , Stasi, Stephanie L. Di, Schmitt, Laura C. , Magnussen, Robert A., Paterno, Mark V. , Flanigan, David C. , Kaeding, Christopher C. , Magnussen, Robert A. , Hewett, Timothy E.

Mayo Clinic

International Journal of Sports Physical Therapy | December 18, 2020 | Volume: 15 | Issue: 6 | Pages: 995-1005

10.26603/ijspt20200995 | PMID 33344016 Get It

Refractory rhabdomyolysis responsive to corticosteroid therapy
Hammers, Marissa, Hashim, Faris , Hanna, Christian , Farris, Amanda C., Blasick, Stephanie , Hanna, Christian , Hammers, Marissa J

Mayo Clinic

Baylor University Medical Center Proceedings | December 14, 2020 | Volume: 34 | Issue: 2 | Pages: 314-315

10.1080/08998280.2020.1851627 | PMID 33678976 Get It

Internal dose escalation associated with increased local control for melanoma brain metastases treated with stereotactic radiosurgery
DeWees, T.A. , Acharya, Sahaja , Mahmood, Mustafaa, Knutson, Nels, Goddu, S , Kavanaugh, James , Rich, Keith M. , Leuthardt, Eric , Dowling, Joshua L. , Dunn, Gavin P. , Perkins, Stephanie M., Tsien, Christina , Robinson, Clifford G. , Abraham, Christopher , DeWees, Todd A , Robinson, Clifford , Kennedy, William R. , Mitchell, Timothy J. , Kim, Albert H. , Chicoine, Michael , Huang, Jiayi

Mayo Clinic

Journal of Neurosurgery | December 11, 2020 | Volume: 135 | Issue: 3 | Pages: 855-861

10.3171/2020.7.jns192210 | PMID 33307528 Get It

OBJECTIVE The internal high-dose volume varies widely for a given prescribed dose during stereotactic radiosurgery (SRS) to treat brain metastases (BMs). This may be altered during treatment planning, and the authors have previously shown that this improves local control (LC) for non–small cell lung cancer BMs without increasing toxicity. Here, they seek to identify potentially actionable dosimetric predictors of LC after SRS for melanoma BM. METHODS The records of patients with unresected melanoma BM treated with single-fraction Gamma Knife RS between 2006 and 2017 were reviewed. LC was assessed on a per-lesion basis, defined as stability or a decrease in lesion size. Outcome-oriented approaches were utilized to determine optimal dichotomization for dosimetric variables relative to LC. Univariable and multivariable Cox regression analysis was implemented to evaluate the impact of collected parameters on LC. RESULTS Two hundred eighty-seven melanoma BMs in 79 patients were identified. The median age was 56 years (range 31–86 years). The median follow-up was 7.6 months (range 0.5–81.6 months), and the median survival was 9.3 months (range 1.3–81.6 months). Lesions were optimally stratified by volume receiving at least 30 Gy (V30) greater than or equal to versus less than 25%. V30 was ≥ and < 25% in 147 and 140 lesions, respectively. For all patients, 1-year LC was 83% versus 66% for V30 ≥ and < 25%, respectively (p = 0.001). Stratifying by volume, lesions 2 cm or less (n = 215) had 1-year LC of 82% versus 70% (p = 0.013) for V30 ≥ and < 25%, respectively. Lesions > 2 to 3 cm (n = 32) had 1-year LC of 100% versus 43% (p = 0.214) for V30 ≥ and < 25%, respectively. V30 was still predictive of LC even after controlling for the use of immunotherapy and targeted therapy. Radionecrosis occurred in 2.8% of lesions and was not significantly associated with V30. CONCLUSIONS For a given prescription dose, an increased internal high-dose volume, as indicated by measures such as V30 ≥ 25%, is associated with improved LC but not increased toxicity in single-fraction SRS for melanoma BM. Internal dose escalation is an independent predictor of improved LC even in patients receiving immunotherapy and/or targeted therapy. This represents a dosimetric parameter that is actionable at the time of treatment planning and warrants further evaluation.
Prenatal characterization of a novel inverted SMAD2 duplication by mate pair sequencing in a fetus with dextrocardia
Zepeda‐Mendoza, Cinthya , Essendrup, Anna, Smoley, Stephanie A., Johnson, Sarah H. , Hoppman, Nicole L., Vasmatzis, George , Jackson, Daniel L. , Kearney, Hutton M. , Zepeda-Mendoza, Cinthya J , Baughn, Linda B.

Mayo Clinic

Clinical Case Reports | December 11, 2020 | Volume: 9 | Issue: 2 | Pages: 769-774

10.1002/ccr3.3608 | PMID 33598243 Get It

AbstractThis case report underlines the importance of molecular characterization of genomic duplications and other structural variants in the prenatal setting to guide clinical interpretation, genetic counseling, and perinatal medical care.